Loading...
Market
Story
Pfizer Reports Q3 2024 Earnings: $17.7B Revenue, Adjusted EPS of $1.06, Raises Guidance; Net Profit Up 6.3%
Oct 29, 2024, 11:09 AM
Pfizer Inc. reported strong third-quarter earnings for 2024, with revenues of $17.7 billion, exceeding analyst estimates of $15.2 billion and marking a 31% year-over-year increase. The company also reported adjusted earnings per share (EPS) of $1.06, significantly higher than the expected $0.64. Following these results, Pfizer raised its full-year guidance, now anticipating adjusted EPS in the range of $2.75 to $2.95, up from a previous estimate of $2.45 to $2.65. Revenue guidance was also increased to between $61.0 billion and $64.0 billion, compared to the prior range of $59.5 billion to $62.5 billion. The strong performance was attributed to robust sales from its Covid-related products, contributing approximately $5 billion from its vaccine and $5.5 billion from Paxlovid. The company's market capitalization stands at $163.54 billion.
View original story
Similar markets
Market cap increases by over 10% • 25%
Market cap increases by 0-10% • 25%
Market cap decreases by 0-10% • 25%
Market cap decreases by over 10% • 25%
Top 1 • 25%
Top 2 • 25%
Top 3 • 25%
Below Top 3 • 25%
Top 1 • 25%
Top 2-5 • 25%
Top 6-10 • 25%
Outside top 10 • 25%
Increase by more than 5% • 25%
Increase by up to 5% • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
Top 3 • 25%
4th to 6th • 25%
7th to 10th • 25%
Outside top 10 • 25%
Outperforms S&P 500 • 25%
Matches S&P 500 • 25%
Underperforms S&P 500 • 25%
Significantly underperforms • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Pfizer • 33%
Johnson & Johnson • 33%
Eli Lilly • 33%